Roquefort Therapeutics (ROQ) Competitors GBX 5.13 -0.47 (-8.43%) (As of 11/1/2024 12:39 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider Trades ROQ vs. C4XD, DDDD, AREC, SAR, OKYO, OBI, AOR, HEMO, RLM, and NSCIShould you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include C4X Discovery (C4XD), 4D pharma (DDDD), Arecor Therapeutics (AREC), Sareum (SAR), OKYO Pharma (OKYO), Ondine Biomedical (OBI), AorTech International (AOR), Hemogenyx Pharmaceuticals (HEMO), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry. Roquefort Therapeutics vs. C4X Discovery 4D pharma Arecor Therapeutics Sareum OKYO Pharma Ondine Biomedical AorTech International Hemogenyx Pharmaceuticals Realm Therapeutics NetScientific Roquefort Therapeutics (LON:ROQ) and C4X Discovery (LON:C4XD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the media favor ROQ or C4XD? In the previous week, Roquefort Therapeutics had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for C4X Discovery. Roquefort Therapeutics' average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score. Company Overall Sentiment Roquefort Therapeutics Neutral C4X Discovery Neutral Which has more risk and volatility, ROQ or C4XD? Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Do analysts recommend ROQ or C4XD? Given C4X Discovery's higher probable upside, analysts plainly believe C4X Discovery is more favorable than Roquefort Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roquefort Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AC4X Discovery 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ROQ or C4XD? C4X Discovery received 88 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRoquefort TherapeuticsN/AN/AC4X DiscoveryOutperform Votes8877.88% Underperform Votes2522.12% Which has preferable valuation and earnings, ROQ or C4XD? C4X Discovery has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort Therapeutics£637.0010,396.88-£1.54M-£0.01-512.80C4X Discovery£24.68M0.00£10.57M£0.04N/A Is ROQ or C4XD more profitable? C4X Discovery has a net margin of 42.81% compared to Roquefort Therapeutics' net margin of 0.00%. C4X Discovery's return on equity of 55.38% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort TherapeuticsN/A -27.05% -15.86% C4X Discovery 42.81%55.38%28.04% Do institutionals & insiders have more ownership in ROQ or C4XD? 1.7% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of C4X Discovery shares are owned by institutional investors. 60.4% of Roquefort Therapeutics shares are owned by insiders. Comparatively, 27.1% of C4X Discovery shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryC4X Discovery beats Roquefort Therapeutics on 12 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROQ vs. The Competition Export to ExcelMetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.62M£159.96M£5.40B£1.59BDividend YieldN/A3.39%5.15%10.99%P/E Ratio-512.80348.23113.761,747.90Price / Sales10,396.8819,593.141,483.04231,381.08Price / Cash1.4911.1439.7136.00Price / Book1.287.754.662.89Net Income-£1.54M-£18.69M£119.06M£144.83M7 Day Performance29.82%0.01%0.79%0.11%1 Month Performance46.51%2.54%5.65%-0.11%1 Year Performance-24.03%27.91%36.80%15.34% Roquefort Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROQRoquefort TherapeuticsN/AGBX 5.13-8.4%N/A-26.7%£6.62M£637.00-512.809High Trading VolumeC4XDC4X DiscoveryN/AGBX 12+27.3%N/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AGBX 16.66flatN/AN/A£30.05M£718,000.00-1.08106ARECArecor TherapeuticsN/AGBX 74-1.3%N/A-59.5%£27.94M£4.90M-264.2910SARSareumN/AGBX 25.20-1.2%N/A-59.2%£27.20M£47,204.00-420.003,211Positive NewsGap DownOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap DownOBIOndine BiomedicalN/AGBX 8flatN/A-23.4%£22.18M£1.63M-266.67N/ANews CoverageGap UpAORAorTech InternationalN/AGBX 123.50-2.4%N/AN/A£19.99M£539,000.00-33.383HEMOHemogenyx PharmaceuticalsN/AGBX 1.34-3.3%N/A-30.8%£18.01MN/A-134.4014Gap DownRLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/A+2.9%£12.81M£1.45M-486.3626 Related Companies and Tools Related Companies C4XD Alternatives DDDD Alternatives AREC Alternatives SAR Alternatives OKYO Alternatives OBI Alternatives AOR Alternatives HEMO Alternatives RLM Alternatives NSCI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:ROQ) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
